Mutum

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mutum

Quick Facts

Property Description
Active ingredient Fluconazole
Pharmacological class Systemic Azole Antifungal
Common use Halting fungal infection progression
Origin Synthetic (Triazole derivative)
Forms Tablets, Capsules, Solution for infusion

What is Mutum and What Class Does It Belong To?

Mutum is a medicinal preparation whose active ingredient is Fluconazole, a synthetic triazole derivative belonging to the systemic azole antifungal pharmacological class. This classification establishes it as an antimycotic agent designed to address infections caused by various pathogenic fungi. Fluconazole is a synthetic compound, which distinguishes it from certain other antifungal agents that may have biological origins.

Composition and Available Preparations

Mutum is consistently formulated as a single-ingredient product, with Fluconazole being the sole active substance. The product is supplied in several distinct dosage forms, which include tablets, hard capsules, powder for oral suspension, and solution for infusion. The availability of the powder for oral suspension, in particular, facilitates administration for specific patient groups, such as children or individuals with difficulty swallowing. These preparations ensure appropriate routes of administration: oral (using solid and liquid forms) and intravenous (using the solution for infusion).

What is the General Therapeutic Purpose of Mutum?

The general therapeutic purpose of Mutum is to halt the progression of fungal infections by compromising the structural integrity of the fungal organism. Fluconazole has systemic activity against a wide variety of susceptible fungal pathogens. The mechanism involves Fluconazole interfering with the fungus's ability to produce ergosterol, a crucial lipid required to maintain the stability of the fungal cell membrane, thereby exerting a fungistatic effect against susceptible organisms. This action stabilizes the infection, supporting the body's natural immune defenses in clearing the compromised fungal organisms.

What side effects are possible with Mutum?

Mutum's safety profile is documented in official regulatory sources, with adverse reactions formally classified by frequency and grouped by the physiological system affected. The effects range from commonly reported, mild reactions to rare, serious events.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized by frequency as defined in prescribing information. Reactions classified as Common include disorders such as headache, nausea, abdominal pain, diarrhea, and rash. Effects considered Uncommon include dizziness, vomiting, hypokalemia, and elevated liver enzyme values. Rare reactions, or those associated with a frequency of Rare or Not Known, are often more clinically significant.

System-Organ Class (SOC) Examples of Rare or Serious Adverse Reactions
Hepatobiliary Disorders Hepatic failure, hepatocellular necrosis, jaundice
Cardiac Disorders QT interval prolongation, Torsade de pointes (a serious heart rhythm disorder)
Skin and Subcutaneous Stevens-Johnson syndrome, Toxic Epidermal Necrolysis
Blood and Lymphatic Agranulocytosis, leukopenia, thrombocytopenia

Safety Considerations and Restrictions

The official label contains specific limitations and safety notes. Use is contraindicated in individuals with a known hypersensitivity to Mutum or other azole compounds. There are explicit constraints regarding co-administration with other medicines that are known to prolong the QT interval and are metabolized via the enzyme CYP3A4. Documentation also notes that Alopecia (hair loss) is often associated with long-term therapy.

Population-Specific Notes: Caution is necessary in patients with pre-existing hepatic impairment due to the potential for serious liver injury, which is not clearly linked to the dose or duration of use. Patients with renal impairment require specific safety considerations due to the drug's primary elimination route.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation characterizes Mutum (Fluconazole) overdose by specific, severe manifestations, requiring immediate medical intervention.


Documented Overdose Presentations and Emergency Action

Category Regulatory Statement
Documented Manifestations Overdose cases may present with central nervous system (CNS) effects, including hallucination and paranoid behavior.
Severe Outcomes The risks associated with overdosage include QT interval prolongation on the electrocardiogram and the potential for Torsades de Pointes, a life-threatening arrhythmia. Serious hepatic toxicity has also been documented.
Immediate Action Required Patients or caregivers must seek immediate medical attention and contact a poison control center or emergency room upon suspected overdose.

Official Management and Treatment

Management of Mutum overdosage is primarily through symptomatic treatment and general supportive measures. A specific pharmacological antidote is not listed in the official prescribing information. Where clinically indicated, procedures such as gastric lavage may be performed. Hemodialysis is documented to be an effective method for reducing plasma concentrations, with a three-hour session decreasing levels by approximately 50%. The documented potential for life-threatening cardiac and hepatic events mandates urgent medical attention.

Therapeutic Uses of Mutum

Mutum is a prescribed treatment primarily focused on helping manage symptoms associated with certain inflammatory disorders. It may also provide relief for patients experiencing musculoskeletal discomfort. The medication is generally intended for use in managing both short-term flare-ups and the ongoing challenges of chronic symptom presentation.

The medicine is used to address a range of conditions, including those resulting in chronic joint stiffness, localized pain, and swelling. This includes helping to improve functional abilities in patients whose mobility is affected by their condition.


Quick Fact: Relief for Inflammatory Discomfort


Eligibility and Restrictions for Use

Who Can and Cannot Use Mutum?

Mutum (Fluconazole) eligibility is determined by official regulatory documentation, defining groups for whom use is permitted, restricted, or absolutely prohibited.


Contraindications and Prohibited Use

Use of Mutum is absolutely contraindicated in patients with known hypersensitivity to fluconazole, related azole antifungal agents, or any excipients in the formulation. It is also prohibited for patients concomitantly receiving specific medications that are known to prolong the QT interval and are metabolized by CYP3A4 (e.g., pimozide, quinidine). Individuals with certain rare hereditary metabolic disorders (such as galactose intolerance) are restricted from using specific oral formulations.


Age and Physiological Restrictions

Population Group Regulatory Status
Adults Generally permitted for use.
Children Generally established for patients 6 months and older for most systemic infections. Use for genital candidiasis is not established. Newborns require modified dosing intervals.
Pregnancy Not recommended unless for life-threatening infections. High-dose, chronic use is contraindicated in the first trimester.
Lactation Not recommended with repeated or high doses; acceptable after a single, low dose.

Condition-Based Restrictions

Use requires caution and monitoring in patients with hepatic impairment (liver dysfunction) and cardiovascular conditions (such as heart failure or specific electrolyte abnormalities). Patients with renal impairment (kidney dysfunction) receiving multiple doses require a mandatory dose adjustment.

What should I know about interactions with other medicines?

Mutum Interactions with other medicines and products

Co-administration of Mutum with certain medications or substances may affect its action or the action of the co-administered product. These drug-drug and drug-substance interactions are typically categorized by their mechanistic effects on the drug's activity or its concentration in the body.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category Specific Interacting Medicine Interaction Mechanism and Effect
Gout Medications Probenecid Increases the blood levels of Mutum, which may lead to an elevated risk of adverse effects.
Hormonal Contraceptives Oral Contraceptives (birth control pills) Mutum may reduce the contraceptive effectiveness, increasing the risk of unintended pregnancy.
Antacids Magnesium- or Aluminium-containing antacids Can decrease the absorption of Mutum from the digestive tract, potentially reducing its overall efficacy.
Diabetes Medications Metformin, Gliclazide, and other specific oral agents Mutum may affect the activity of these antidiabetic medications. It can also cause false-positive results on urine glucose tests.

Other Interaction-Related Notes

Regulatory information advises caution regarding concomitant alcohol intake. The combination may lead to increased central nervous system effects such as drowsiness or dizziness, potentially impairing the ability to operate machinery or drive. Patients should consult a healthcare provider regarding all concurrent therapies, including over-the-counter products and herbal supplements, to manage interaction risks.

Mechanism of Action

How Mutum Works

The mechanism of Mutum involves a highly targeted biological process centered on the selective inhibition of a critical enzyme in the fungal cell. This disruption of fungal cell membrane synthesis results in growth inhibition of susceptible fungi.


Molecular Target: Inhibition of Lanosterol Demethylase

This mechanism involves the drug's active ingredient acting as a highly selective competitive inhibitor of the fungal enzyme, lanosterol 14 alpha-demethylase. By blocking this specific P450 enzyme, the drug prevents the conversion of lanosterol into ergosterol, a primary sterol essential for fungal membrane integrity and function.


Cascade Effect: Destabilization of the Fungal Cell Membrane

The resulting deficiency of ergosterol, coupled with the toxic accumulation of methylated sterol precursors within the cell, leads to the destabilization of the fungal cell membrane. This structural failure causes excessive permeability and dysfunction of critical metabolic processes, which ultimately results in the inhibition of fungal cell proliferation and functional compromise.

Dosage and Administration Information

How to Use Mutum — Administration Guidelines

This section outlines the usage instructions for Mutum.

Administration and Timing

Mutum tablets are for oral use only. To ensure proper absorption, the medicine is taken with food.

Administration Rule Procedure
Route & Preparation Swallow the tablet whole with water. Do not crush, chew, or break the tablet.
Dosing Schedule The full prescribed course must be completed as directed by the healthcare provider. The frequency is typically at regular intervals (e.g., daily or twice daily).
Age Restriction Generally, use is not recommended for children under 12 years of age.

Procedure for Missed Doses

Adherence to the prescribed schedule is important for effective use. If a dose is missed, patients should follow these steps:

  1. Take the missed dose as soon as it is remembered.
  2. If the time is near for the next scheduled dose, skip the missed dose entirely.
  3. Resume the regular dosing schedule.
  4. Do not double the dose to make up for the skipped dose.

Use Protocol

These instructions define the approach to using Mutum. The protocol involves swallowing the medicine intact and coordinating the intake with meals. Patients must adhere to the dosing frequency and duration set by the prescriber, following specific steps for any missed dose to maintain consistency with the administration instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mutum (Fluconazole)


Research Evidence for Mucosal Fungal Infections (Oropharyngeal and Esophageal Candidiasis)

Studies for these conditions primarily involve Randomized Controlled Trials (RCTs) that examine clinical and mycological outcomes in adults, including immunocompromised patients, and pediatric populations. The research describes measurements recorded during short study periods, focusing on the rate at which symptoms were reported to evolve and measured outcomes of fungal clearance. The evidence base has been used by regulatory bodies in the context of authorizing its use for these conditions. Data regarding long-term recurrence rates remain limited for some subgroups, and research is ongoing to characterize the clinical implications of certain fungal species that have demonstrated reduced susceptibility in laboratory settings.


Research Evidence for Fungal Infections Affecting the Whole Body (Systemic Candidiasis and Cryptococcal Meningitis)

This evidence is drawn from multi-center comparative trials and meta-analyses that explore outcomes such as mortality rates and clinical success in patients with serious, deep-seated fungal infections. Fluconazole was evaluated in populations including critically ill adults and very low birth weight children. Findings describe patterns observed in these studies, reporting measured outcomes related to patient survival and the resolution of infection in the body. While the evidence contributes to the broader evidence landscape, comparative evidence against newer agents is lacking in some areas, and findings were mixed when comparing different antifungal drug classes across varied, severely ill populations.


Evidence in Special Populations and Key Evidence Gaps

Fluconazole was observed in multiple trials for pediatric populations, including neonates and infants, with research focusing on both treatment and prophylaxis of invasive fungal infections. A substantial portion of the original research also explored its use in immunocompromised adults (e.g., HIV/AIDS patients). For certain rare patient subgroups, data for certain groups remain insufficient. Research is ongoing regarding drug resistance and the optimal dosing and treatment duration for some severe, deep-seated infections are areas where certainty remains low, requiring scientific attention and ongoing study.

Key Studies & References

  1. Fluconazole - StatPearls - NCBI Bookshelf (Regulatory and General Indication Summary)
  2. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis
  3. What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Mutum (FAQ)

Q: How quickly can a person generally expect to notice the effects of Mutum?

A: Studies and official information indicate that the highest concentration of the drug in the blood is generally reached within one to two hours after taking an oral dose. Steady concentrations in the plasma are typically reached after five to ten days of regular dosing.


Q: Does Mutum cause weight gain or loss, according to research?

A: Official research evidence does not list primary weight gain or loss as a common side effect of Mutum. However, weight loss has been documented as a symptom of a rare, serious adverse reaction known as adrenal insufficiency, as noted in the official product information.


Q: Is it common to feel tired when starting Mutum?

A: Official prescribing information notes that general fatigue or asthenia (lack of energy) is an uncommon side effect. Unusual tiredness or weakness may also be a sign of a rare, serious condition, such as adrenal insufficiency.


Q: Are there any specific foods I should avoid while using Mutum?

A: According to the official drug label, studies have shown that the amount of the drug absorbed into the body is not affected by food. Official studies show the medication's absorption is not affected by food.


Q: Is Mutum known to interact with common pain relievers like ibuprofen?

A: Official drug interaction data indicates that co-administering Mutum with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen can increase the concentration of the pain reliever in the body. This interaction may lead to an increased risk of side effects from the ibuprofen.


Q: Does Mutum affect blood pressure or heart rate?

A: Regulatory documents state that Mutum can be associated with a risk of QTc prolongation, which is a potentially serious heart rhythm issue. Additionally, low blood pressure has been reported as a symptom of a rare, severe side effect. Official safety warnings note caution is warranted due to the drug's effect on the heart rhythm.


Q: How long does Mutum stay in a person's system after the last dose?

A: The regulatory information describes the terminal elimination half-life of Mutum as approximately 30 hours. This extended half-life means that it can take several days for the medicine to be fully cleared from the body after the last dose is taken.


Q: Does Mutum have a black box warning or similar strong caution in the US or Europe?

A: The FDA issued a strong caution for chronic, high-dose use of the medicine (400 to 800 mg/day) during the first trimester of pregnancy, indicating a potential human fetal risk based on available data. This is an important safety communication from the FDA.


Q: Why is Mutum described as having an effect on [high-level body system, e.g., 'nerve signals']?

A: The official mechanism of action is focused on the fungal cell itself. The drug works by blocking a specific enzyme (lanosterol 14-alpha-demethylase) that is essential for the fungal cell membrane's structure, which interferes with the fungal organism's ability to grow.


Q: Are there any specific mental health conditions that prevent the use of Mutum?

A: The official product information notes contraindications regarding the co-administration of Mutum with several medications used to treat certain mental health conditions. This is due to the potential for serious cardiotoxicity when taken alongside drugs like pimozide or quinidine.


Q: What are the signs of a serious allergic reaction to Mutum?

A: Regulatory documents list symptoms that may indicate a severe reaction, which include a spreading rash, fever, peeling skin, or swelling of the face, lips, or throat. Serious allergic reactions, including anaphylaxis and severe skin disorders like Stevens-Johnson syndrome, have been reported.


Q: Are there different strengths or dosages of Mutum available?

A: The official product labeling confirms that the tablets containing the active ingredient, fluconazole, are available in multiple strengths. Common strengths listed in regulatory documents include 50 mg, 100 mg, 150 mg, and 200 mg.


Q: Does Mutum affect fertility in men or women?

A: According to authoritative sources, studies have not been conducted in humans to determine if Mutum affects male or female fertility. Official drug information focuses primarily on the effects during pregnancy and lactation.


Q: Why does the packaging for Mutum include a warning about sunlight exposure?

A: The official drug molecule is known to have photosensitive properties, and severe dermatologic reactions have been reported. Some official information advises patients to take precautions, such as avoiding excessive exposure to sunlight, to mitigate potential skin-related effects.


Q: What is the risk of overdose associated with Mutum?

A: Official documentation regarding overdose reports that symptoms may include alterations in behavior. Specifically, there have been reports of patients experiencing hallucination and paranoid behavior following exposure to doses higher than prescribed.


Q: What happens if I stop taking Mutum suddenly?

A: The prescribing information strongly emphasizes the need to complete the full prescribed course of the drug. Mutum has a relatively long half-life, meaning it stays in the system for about 30 hours after the last dose. Discontinuation due to rash is advised for superficial infections if lesions progress.


Q: Is there a generic version of Mutum available?

A: Official product information confirms that the active ingredient in Mutum is fluconazole. Fluconazole is a well-established compound, and generic versions of the drug are available in various forms and strengths.

How should Mutum be stored and disposed of?

Storage and Disposal Requirements for Fluconazole (Mutum)


Mandatory Storage Conditions

Fluconazole must be stored within formulation-specific temperature ranges. Tablets and dry powder must be stored below 30°C (86°F) and kept in a dry place. The reconstituted oral suspension requires storage between 5°C and 30°C (41°F and 86°F).

All forms must be protected from freezing and kept in the original container, which must remain tightly closed.

Stability, Safety, and Disposal

The reconstituted oral suspension has a strict in-use stability limit and must be discarded after 14 days from mixing. For child safety, the medicine must be kept out of the sight and reach of children and pets, with official labeling advising to store locked up.

Disposal of unused or expired product must follow all local and national regulations. Medicines must not be thrown away via wastewater or released to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mutum found in:

A-Z Index: